You are invited to participate in a “Drisapersen Update” webinar with GSK. The purpose of the webinar is to update the Duchenne community about Phase II clinical trial results for GSK’s drisapersen drug for the treatment of Duchenne muscular dystrophy. GSK investigator John Kraus will present and answer submitted questions. PPMD, CureDuchenne, and MDA will co-sponsor this webinar.
If you have questions you would like to submit, please email email@example.com with “Drisapersen Update” as the subject line. We will pass along all questions to GSK prior to the webinar. Please submit your questions no later than Thursday, May 2.
Click here to register for this webinar.